cyrilzakka/clinical-trials huggingface dataset:
Pea Protein and Postprandial Response (PEA)

The main objective is to investigate the postprandial effect of arginine-rich protein (i.e. pea-protein) on metabolic control, inflammation and endothelial function after a high-fat meal in subjects with characteristics of the metabolic syndrome.

Arginine is potential interesting considering the metabolic syndrome. Studies so far indicated both long-term effects, as well as acute - postprandial - actions; especially when metabolism is already challenged, e.g. in diabetic patients or after a high-fat meal. If arginine-rich proteins are equally effective is not known. Therefore we are interested in the effect of (arginine rich) protein on postprandial (dys)metabolism, inflammation and endothelial function, within 6 hours after a meal.

Eligibility Criteria:
Inclusion Criteria:

* male gender
* central obesity: waist circumference ≥94 cm

plus any one of the following four factors:

* raised triglyceride level: ≥1.7 mmol/L;
* reduced high-density lipoprotein (HDL) cholesterol: \<1.03 mmol/L
* raised blood pressure: systolic blood pressure ≥130 mmHg or diastolic BP ≥85 mmHg or use of blood pressure lowering medication
* raised fasting plasma glucose ≥ 5.6 mmol/L

Additional inclusion criteria:

* age 45-70 years
* body weight should be stable for 3 months
* stable exercise habits during the last 6 months, and not participating in any vigorous exercise program

Exclusion Criteria:

* tobacco smoking
* (undiagnosed) diabetes - but not impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) as evaluated by an oral glucose tolerance test at screening
* active hearth disease, i.e. history of myocardial infarction or angina pectoris
* following, or have recently followed a (weight-loss) diet
* drug uses knowing to interfere with the objectives of the study
* oral corticosteroids, lipid-lowering drugs (statins)
* allergic to cow milk / dairy products or gluten
* vegetarians
* received inoculations within 2 months of starting or planned to during the study
* donated or intended to donate blood 2 months before till two months after the study
* abuse of drugs and/or alcohol
* participation in another biomedical study within 1 month before the first screening visit
* not agreeable to be informed about possible distorted blood values which could be found by screening
Development for the Peritoneal Carcinomatosis Index (PCI) in Ovarian Cancer

* Primary objectives: To develop peritoneal carcinomatosis index (PCI) for ovarian cancer, tubal cancer and primary peritoneal cancer that can represent perioperative intraperitoneal tumor burden objectively
* Secondary objectives: To establish the relationship and find out clinical significance between PCI, tumor location and tumor characteristics

Patients with primary ovarian cancer

* Informed consent
* Digital photography \& Checking PCI (tumor size, number, and Characteristics)
* Postoperative surveillance(tumor marker, image and physical examination)

  1. Developing the best fitting PCI model to reflect recurrence-free survival and overall survival

     * Selection of items
     * Weighting by items and tumor characteristics
  2. Analysis of prognostic impact of PCI compared to conventional staging system (FIGO stage) for ovarian cancer

Eligibility Criteria:
Inclusion Criteria:

1. Preoperative clinical diagnosis of ovarian cancer, tubal cancer, and primary peritoneal carcinoma (all stage)
2. Available preoperative image study (CT and/or MRI and/or PET)
3. Patients who gave a written informed consent
4. Patients must be surgical candidate considering medical and psychological condition

Exclusion Criteria:

* Patients who refuse to participate or want to withdraw at anytime.
Consumer Assessment of Tobacco Flavor and Odor

This trial studies consumer assessments of tobacco flavor and odor. This study will compare the ability of expert and consumer panels to identify and characterize flavors, determine threshold detection levels for individual and mixed flavors, and identify the dominant flavor of mixtures.

PRIMARY OBJECTIVE:

I. Develop consumer (untrained) sensory panels to identify and assess characterizing flavors in electronic (e)-liquids.

OUTLINE:

Non-user panelists smell and user panelists puff flavored e-liquids and answer questions about the products.

Eligibility Criteria:
Inclusion Criteria:

* CONSUMER USER: Current daily vapers of products containing nicotine
* CONSUMER USER: No concurrent use of other tobacco products
* CONSUMER USER: General good health
* CONSUMER USER: No allergies
* CONSUMER USER: No self-reported taste or smell deficits
* CONSUMER USER: Not pregnant or lactating
* CONSUMER USER: No medications known to interfere with taste/smell
* CONSUMER USER: Passing scores on the Brief Smell Identification Test (B-SIT), phenylthiocarbamine (PTC) and 6-n-propylthiouracil (PROP) smell and taste tests
* CONSUMER USER: No positive diagnosis of COVID-19 within 30 days
* CONSUMER NONUSER: No use of tobacco or nicotine products in the last year
* CONSUMER NONUSER: General good health
* CONSUMER NONUSER: No allergies
* CONSUMER NONUSER: No self-reported taste or smell deficits
* CONSUMER NONUSER: Not pregnant or lactating
* CONSUMER NONUSER: No medications known to interfere with taste/smell
* CONSUMER NONUSER: Passing scores on the Brief Smell Identification Test (B-SIT), phenylthiocarbamine (PTC) and 6-n-propylthiouracil (PROP) smell and taste tests
* CONSUMER NONUSER: No positive diagnosis of COVID-19 within 30 days

Exclusion Criteria:

* CONSUMER USER: Outside age range
* CONSUMER USER: Not current daily vapers
* CONSUMER USER: Concurrent use of other tobacco products
* CONSUMER USER: Fair or poor general health
* CONSUMER USER: Allergies
* CONSUMER USER: Self-reported taste or smell deficits
* CONSUMER USER: Pregnant or lactating
* CONSUMER USER: Medications known to interfere with taste/smell
* CONSUMER USER: Failing scores on the Brief Smell Identification Test (B-SIT), phenylthiocarbamine (PTC) and 6-n-propylthiouracil (PROP) smell and taste tests
* CONSUMER USER: Positive diagnosis of COVID-19 within 30 days
* CONSUMER NONUSER: Outside age range
* CONSUMER NONUSER: Use of tobacco or nicotine products in the last year
* CONSUMER NONUSER: Fair or poor general health
* CONSUMER NONUSER: Allergies
* CONSUMER NONUSER: Self-reported taste or smell deficits
* CONSUMER NONUSER: Pregnant or lactating
* CONSUMER NONUSER: Medications known to interfere with taste/smell
* CONSUMER NONUSER: Failing scores on the Brief Smell Identification Test (B-SIT), phenylthiocarbamine (PTC) and 6-n-propylthiouracil (PROP) smell and taste tests
* CONSUMER NONUSER: Positive diagnosis of COVID-19 within 30 days
Chronic Diarrhea Owing to Underlying Microscopic Colitis

The goal of this observational study is to search for accurate diagnoses for patients with chronic diarrhea and assess the prevalence of microscopic colitis. The main question\[s\] it aims to answer \[is/are\]:

Does microscopic colitis account for a significant portion of patients with chronic diarrhea?

Participants will subjected to:

* Routine laboratory examination.
* Colonoscopy: A total colonoscopy will be done with visualization of the terminal ileum. Biopsies will be taken from each segment of the colon and any abnormal appearing areas, the right-sided colon (cecum, ascending colon, and transverse colon), the left-sided colon (descending colon and sigmoid colon), and the rectum.


Eligibility Criteria:
Inclusion Criteria:

* Patients with chronic watery diarrhea

Exclusion Criteria:

* Infectious colitis.
* Inflammatory bowel diseases (ulcerative colitis, Crohn's disease, and indeterminate colitis).
* Systemic disease associated with chronic diarrhea, e.g. Diabetes mellitus and Thyroid disease.
* Drugs causing chronic diarrhea, e.g. antibiotics, antidepressants, and angiotensin-converting enzyme inhibitors.
* Chronic diarrhea of decreased digestion as in pancreatic insufficiency and bile acid deficiency.
Treatment Outcomes of Advanced Neoplasia in IBD

In this study, we aimed to (1) compare cumulative incidences of synchronous and metachronous colorectal neoplasia as well as mortality following AN in CD and UC patients who underwent proctocolectomy, (sub)total colectomy, partial colectomy or endoscopic resection, and (2) to determine factors associated with AN treatment choice.

In this retrospective multicenter cohort study, using PALGA (the Dutch nationwide pathology databank), partial colectomy yielded a similar metachronous neoplasia risk compared to (sub)total colectomy after treatment of advanced neoplasia in inflammatory bowel disease. High metachronous neoplasia rates after endoscopic resection underline the importance of strict subsequent endoscopic surveillance.

Eligibility Criteria:
Inclusion Criteria:

* IBD (ulcerative colitis (UC), CD or IBD-unclassified (IBD-U))
* Histological diagnosis of colorectal AN
* Available treatment data

Exclusion Criteria:

* Familial CRC syndrome
* AN prior to IBD diagnosis
Assessment of the Health Improvement of Obese Patients After Fecal Microbiota Transplantation (FMT)

Search for mechanisms of the effect of fecal microbiota transplantation on patients with obesity

1. To select recipients of fecal samples according to eligibility criteria;
2. To perform fecal microbiota transplantation for patients with obesity;
3. To analyze the efficacy of fecal microbiota transplantation for patients with obesity within six months after therapy.

Eligibility Criteria:
Inclusion Criteria:

* age of patients - from 18 to 75 years, both sexes;
* patients with obesity (body mass index ≥40
* patient's informed consent to perform fecal microbiota transplantation

Exclusion Criteria:

* presence of a concomitant chronic infectious disease or malignancy
* patients with a proven allergy to foods not excluded from the donor's diet
* absence of the patient for one or more intermediate stages of the examination.
* informed refusal to continue therapy
A Study to Tailor Advance Directives

In this study, hospitalized patients will first be surveyed regarding their interest in a traditional advanced directive (AD) and then in a modified AD.

The purpose of this study is to assess whether patients will execute an advance directive which offers a limited trial of life-sustaining therapy in non-terminal illness, declines life-sustaining therapy or artificial nutrition in advanced dementia, or declines life-sustaining therapy in general. Advance directives (ADs) as currently drafted have been questioned since they have not had much effect on end-of-life care. However, the reason for the lack of success may be simply that they rarely apply. Traditional ADs, which are limited to terminal illness or persistent vegetative states, are difficult to apply to the more common cases of critical illness in the setting of potentially reversible disease and advanced dementia, which are often not recognized as terminal. In addition, terminal ADs are drafted too narrowly for patients who do not wish for life-sustaining therapy regardless of condition.

Patients may execute either AD at the conclusion of the survey. This research has the potential to demonstrate widely reproducible methods on which more precise advance planning can be based and thereby improve end-of-life care.

Eligibility Criteria:
Inclusion Criteria:

* Hospitalized patients admitted to the general medical service at the University of Chicago
* Previously enrolled in a study of hospitalized general medicine patients at the University of Chicago

Exclusion Criteria:

* Patients who score less than 17 out of 30 on the Folstein Mini-Mental Status Examination or who have a proxy decision-maker
* Patients who are medically unstable based on two or more abnormal vital signs
* Patients who face a possible new diagnosis of cancer
A Naturalistic Study of Adolescents and Young Adults in Treatment for Opioid Dependence

Many buprenorphine treatment programs do not have services dedicated to adolescents and young adults. As a precursor to developing and evaluating an adolescent and young adult buprenorphine treatment program at APT Foundation Inc, we propose to conduct a 1 year prospective study of 16 to 25 year old treatment-seeking individuals enrolled in the APT Adolescent and Young Adult Suboxone Program

Participants will consent to in-person assessments and monthly chart reviews. We anticipate that the results from this study will inform the development of future services targeted towards adolescents and young adults with opioid dependence.

Eligibility Criteria:
Inclusion Criteria:

* Ages 16 through 25 at time of induction
* Meet criteria for enrollment in the APT Adolescent and Young Adult Suboxone Program (Opioid Dependence per DSM-V criteria; no contraindications to buprenorphine (concomitant benzodiazepine, alcohol use, sedative use),
* Stable enough to participate in outpatient care/intensive outpatient care for at least 12 weeks;
* Can commit to at least 12 weeks of treatment through the APT Adolescent and Young Adult Suboxone Program
* Are willing to provide locator information for follow-up.
* Are fluent in English and have a 6th grader or higher reading level

Exclusion Criteria:

* Have an untreated bipolar or schizophrenic disorder, or active suicidal ideation
* Are physically dependent on alcohol, benzodiazepines, or other sedatives.
* Are in custody of the Department of Children and Families
Evaluation of a New Blood Glucose Meter System With Capillary and Venous Blood

The purpose of the study was to evaluate the performance of the meter system in the hands of subjects and healthcare professionals (HCPs). It also evaluated the product user guides in the hands of untrained subjects.

The study evaluated the performance of the blood glucose meter system (BGMS) compared to a laboratory glucose method. Subjects and healthcare professionals tested subject capillary blood and healthcare professionals tested subject venous blood. Two meter configurations were evaluated. The study evaluated the acceptability of product labeling in enabling subjects to perform blood glucose testing with the new meter system and for using meter features. Subjects and healthcare professionals provided feedback about the BGMS and its features.

Eligibility Criteria:
Inclusion Criteria:

* Have type 1 or type 2 diabetes
* Be \> 18, \< 76 year of age at time of consent, with approximately 50% (+10%)being less than 55 years of age
* Be willing to complete all study procedures
* Be routinely testing their blood sugar at home (at least once per day)
* Be able to speak, read, and understand English and understand the Informed Consent document
* Be able to read the labeling instructions

Exclusion Criteria:

* Minors \< 18 years of age and adults \> 75 years of age
* Pregnancy
* Physical (dexterity), visual, or neurological impairments that would make the person unable to perform testing with the BGMS
* Disorders in the fingertip lancing areas
* Acute or chronic infections, particularly skin infections
* Infection with a blood borne pathogen
* Taking prescription anti-coagulants or having clotting problems that may prolong bleeding. Taking aspirin daily (81 mg or 325 mg) is not reason for exclusion
* Hemophilia or any other bleeding disorder
* Having a condition which, in the opinion of the Principal Investigator or designee, would put the person at risk or seriously compromise the integrity of the study
* Working for a competitive medical device company
Cardiac Output Pulmonary Arterial Catheter Compared to FloWave™ 1000

The purpose of this study is to compare cardiac output results obtained using the thermodilution push technique with the Pulmonary Arterial Catheter (PAC) to the predicted cardiac output results obtained from the non-invasive FloWave™ 1000 device.


Eligibility Criteria:
Inclusion Criteria:

* Adults Only: The FloWave device is intended for use on adult patients only. All subjects will be 18 years or older.
* Existing placement of a Pulmonary Arterial Catheter placed for medical reasons other than our study.

Exclusion Criteria:

* Patients with aortic balloon pumps and cardiac mechanical assist devices will be excluded from study enrollment if the devices are present during the screening process. If patients have cardiac assist devices inserted after enrollment in the study, cardiac output data will be collected with both the PAC and FloWave device and will be evaluated as a subset analysis population at the conclusion of the study.
* Patients with intracardiac shunts will be excluded from this study.
* FloWave cardiac output determinations are dependent on detection of a pulse. If no peripheral pulse can be detected the device will not be able to perform a measurement and this will be indicated to the user.
* Patients who are not in a steady hemodynamic state shall be excluded from the study.
* Presence of arrhythmias: Patients with arrhythmias are excluded from the study when not in a steady hemodynamic state. If a patient has a history of arrhythmia or is currently experiencing an arrhythmia but is in a maintained hemodynamic state, they will not be excluded from enrollment into the study. Their clinical symptoms and cardiac rhythm will be evaluated and noted in the patient data record.
* Inability or unwillingness of subject or the subject's legally authorized representative to give informed consent.
Clinical Effects of Ganshuang Combined TDF to Treat CHB and NAFLD

The changes in liver function, body mass index, controlled attenuation parameters, liver stiffness and HBV-DNA at different time points in each group before and after treatment were counted to explore the clinical efficacy of Ganshuang granules combined with tenofovir in the treatment of CHB complicated with NAFLD.

92 patients included in the study were randomly divided into 2 groups, 42 patients in the control group and 50 patients in the treatment group. Both groups of patients received conventional basic treatment such as liver protection. Moreover, in both groups, patients were instructed to change their dietary structure to control low-fat and low-sugar, and were instructed to perform appropriate aerobic exercise.

The control group was treated with silymarin glucosamine tablets (Jiangsu Zhongxing Pharmaceutical Co., Ltd.; National medicine permission number: H32026233; Production batch: 200304) and tenofovir (QILU Pharmaceutical Co., Ltd.; National medicine permission number: H20173185; Production batch: 1L0694DF6). The use of silymarin glucosamine tablets was 0.2g/d, 3 times/d for 24 weeks; the use of tenofovir was 300mg/d, 1 time/d for 24 weeks.

The treatment group was treated with Ganshuang granules (Baoding Tianhao Pharmaceutical Co., Ltd.; National medicine permission number: Z20027671; Production batch: 200326 ) combined with silibinin meglumine tablets and tenofovir. Libribin meglumine tablets and tenofovir were used in the same way as in the control group, and Ganshuang granules were used 3 g/time, 3 times/d, and the course of treatment was 24 weeks.

Eligibility Criteria:
Inclusion Criteria:

Chronic hepatitis B patients not treated with antiviral drugs； Fatty liver was diagnosed by B-ultrasound and imaging； No history of excessive drinking； Good drug compliance and regular medication； Exclusion Criteria： Non chronic hepatitis B patients； Taking other drugs； liver failure, liver cancer and other diseases； patients who refused to sign informed consent；
Using Flexible Resin in Maxillary Obturators

Ten patients who had had maxillectomy will be assigned to two groups employing two types of 'temporary obturators. The obturators in the first group will be made from heat cure acrylic resin, whereas those in the second group from flexible resin.

A comparison will be made between the two materials in terms of oral-nasal seal using the drinking water test as well as the mirror test.

Oral rehabilitation following partial maxillectomy presents numerous clinical and technical issues. Using soft-tissue undercuts in the palatal side of the upper jaw is so useful for prostheses' retention over and above the abutment teeth. The use of flexible materials can serve this aim. The current study aims to compare the efficacy of nasal-oral seal using flexible materials against the traditional method of using heat activated acrylic materials.

Eligibility Criteria:
Inclusion Criteria:

* patient who had partial or complete maxillectomy
* two weeks should have passed at least before being included in the study.
* patient should have completed their radiotherapy.

Exclusion Criteria:

* patients under the age of 10 years
* patients who had had their operations more than five months before the being recruited.
* patients who are under radiotherapy when asked to participate in the study.
Postoperative Chewing Gum and Gynecological Laparoscopic Surgery

The authors aimed to evaluate the effects of postoperative gum chewing on laparoscopic gynecological surgery, gastrointestinal function-intestinal mobility and early postoperative recovery. Patients undergoing elective gynecological laparoscopy were randomized. Demographic and characteristic features of the patients were recorded. Operation type, operation and anesthesia information were recorded. Patients underwent a postoperative routine regimen. Starting from the sixth hour, the sugar-free gum was crushed every 15 minutes until the gas was released. Postoperative follow-up was performed routinely. The first bowel movements, first bowel movements and first gas extraction and first decongestation periods were recorded.

The team of the research team of the research team will listen and record the bowel sounds of the patients, using a stethoscope every two hours starting from the postoperative 3rd hour until the first bowel sounds are heard in each patient.

Patients who were able to tolerate patients starting from the 8th hour after the surgery were allowed for mobilization. Also, they were allowed to take fluid regimen from the postoperative 12th hour. Patient satisfaction was evaluated by using visual analogue scale (VAS) on the day of discharge on chewing postoperative.

The primary index for the return of GI functions was the first gas removal time. Secondary index was the time of first bowel sound, the first time of admission, hospitalization time and the presence of postoperative ileus.

Eligibility Criteria:
Inclusion Criteria:

* Patients undergoing elective laparoscopic gynecological surgery.

Exclusion Criteria:

* Those who have been operated for malignant reasons,
* Those who underwent emergency surgery,
* Who could not chew gum,
* Who had serious surgical complications (postoperative intraabdominal hemorrhage, infection, peritonitis),
* Who had a history of gastrointestinal disease,
* Secondary laparotomy.